Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912280 | 1.00 | BUB1 (0.34) | BUB1PRCPMEN1KMT2ANOS1 | |
| SCHEMBL19512616 | 1.00 | BUB1 (0.34) | BUB1PRCPMEN1KMT2ANOS1 | |
| SCHEMBL25053491 | 0.86 | CHRNB2 (0.33) | BUB1PRCPMEN1KMT2ASLC6A2 | |
| SCHEMBL29891891 | 0.86 | CHRNB2 (0.33) | BUB1PRCPMEN1KMT2ASLC6A2 | |
| SCHEMBL17514153 | 0.86 | CHRNA7 (0.33) | SLC6A2SLC6A3 | |
| SCHEMBL451170 | 0.84 | HTR2A (0.35) | KMT2ASLC6A2HTR2BSLC6A3 | |
| SCHEMBL433152 | 0.84 | HTR2A (0.35) | KMT2ASLC6A2HTR2BSLC6A3 | |
| SCHEMBL431587 | 0.84 | HTR2A (0.35) | KMT2ASLC6A2HTR2BSLC6A3 | |
| SCHEMBL5770510 | 0.81 | HTR2C (0.35) | BUB1MEN1KMT2ASLC6A2HTR2B | |
| SCHEMBL5770518 | 0.81 | HTR2C (0.35) | BUB1MEN1KMT2ASLC6A2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | GENENTECH, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11478438-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2022-10-25 | — | — | US | disclosed |
| US-20210139504-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| CN-107108492-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2021-03-19 | — | — | CN | disclosed |
| US-20200182617-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-06-11 | — | — | US | disclosed |
| US-10555920-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-11 | — | — | US | disclosed |
| US-20190038578-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-02-07 | — | — | US | disclosed |
| US-10092529-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-10-09 | — | — | US | disclosed |
| EP-3224245-A1 | NECROSIS INHIBITORS | National Institute Of Biological Sciences, Beijing (CN) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016101887-A1 | NECROSIS INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478438-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | BUB1 1654/4885PRCP 4720/4885MEN1 3176/4885 |
| US-20210139504-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | BUB1 843/4885PRCP 3262/4885MEN1 965/4885 |
| US-20190038578-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | BUB1 1654/4885PRCP 4720/4885MEN1 3176/4885 |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | HSD17B7, CYP11B1, CYP11B2 | BUB1 843/4885PRCP 3262/4885MEN1 965/4885 |
| US-10092529-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | BUB1 2716/4885PRCP 4691/4885MEN1 3275/4885 |
| US-10555920-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | BUB1 1654/4885PRCP 4720/4885MEN1 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.